Venus Remedies Limited (VENUSREM.BO)
INR 307.35
(3.03%)
INR 307.35
(3.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -267.7 Million INR | -226.99% |
| 2022 | 210.81 Million INR | 5234.19% |
| 2021 | -4.1 Million INR | -101.83% |
| 2020 | 224.39 Million INR | -89.73% |
| 2019 | 2.18 Billion INR | -26.17% |
| 2018 | 2.95 Billion INR | -3.4% |
| 2017 | 3.06 Billion INR | -1.36% |
| 2016 | 3.1 Billion INR | -6.14% |
| 2015 | 3.3 Billion INR | 3.26% |
| 2014 | 3.2 Billion INR | 11.09% |
| 2013 | 2.88 Billion INR | 7.45% |
| 2012 | 2.68 Billion INR | 22.16% |
| 2011 | 2.19 Billion INR | 158.94% |
| 2010 | 848.65 Million INR | -42.27% |
| 2009 | 1.46 Billion INR | 13.07% |
| 2008 | 1.3 Billion INR | 37.45% |
| 2007 | 945.84 Million INR | 15.27% |
| 2006 | 820.56 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -375.2 Million INR | 0.0% |
| 2024 Q1 | - INR | 100.0% |
| 2023 Q2 | 372.1 Million INR | -47.84% |
| 2023 Q3 | 707.5 Million INR | 90.14% |
| 2023 Q4 | -267.7 Million INR | -137.84% |
| 2023 Q1 | 713.44 Million INR | 238.43% |
| 2023 FY | -267.7 Million INR | -226.99% |
| 2022 Q2 | -177.9 Million INR | -141.13% |
| 2022 FY | 210.81 Million INR | 5234.19% |
| 2022 Q4 | 210.81 Million INR | -67.54% |
| 2022 Q3 | 649.5 Million INR | 465.09% |
| 2022 Q1 | 432.55 Million INR | 10634.73% |
| 2021 Q3 | 414.48 Million INR | 256.14% |
| 2021 Q4 | -4.1 Million INR | -100.99% |
| 2021 Q1 | 289.79 Million INR | 29.14% |
| 2021 Q2 | 116.38 Million INR | -59.84% |
| 2021 FY | -4.1 Million INR | -101.83% |
| 2020 FY | 224.39 Million INR | -89.73% |
| 2020 Q3 | 60.67 Million INR | -90.01% |
| 2020 Q2 | 607.46 Million INR | 0.0% |
| 2020 Q4 | 224.39 Million INR | 269.86% |
| 2019 Q4 | 2.18 Billion INR | 1384.83% |
| 2019 FY | 2.18 Billion INR | -26.17% |
| 2019 Q2 | 1.8 Billion INR | 2058.23% |
| 2019 Q1 | 83.76 Million INR | -97.17% |
| 2019 Q3 | 147.16 Million INR | -91.86% |
| 2018 FY | 2.95 Billion INR | -3.4% |
| 2018 Q4 | 2.95 Billion INR | 0.0% |
| 2017 FY | 3.06 Billion INR | -1.36% |
| 2016 FY | 3.1 Billion INR | -6.14% |
| 2016 Q4 | 2.77 Billion INR | 0.0% |
| 2015 FY | 3.3 Billion INR | 3.26% |
| 2014 FY | 3.2 Billion INR | 11.09% |
| 2013 Q4 | 2.88 Billion INR | 0.0% |
| 2013 FY | 2.88 Billion INR | 7.45% |
| 2012 Q4 | 2.68 Billion INR | 0.0% |
| 2012 Q2 | 232.95 Million INR | 0.0% |
| 2012 FY | 2.68 Billion INR | 22.16% |
| 2011 FY | 2.19 Billion INR | 158.94% |
| 2010 FY | 848.65 Million INR | -42.27% |
| 2009 FY | 1.46 Billion INR | 13.07% |
| 2008 FY | 1.3 Billion INR | 37.45% |
| 2007 FY | 945.84 Million INR | 15.27% |
| 2006 FY | 820.56 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 99.631% |
| NATCO Pharma Limited | -5.81 Billion INR | 95.398% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 284.651% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 679.299% |
| Achyut Healthcare Limited | -3.74 Million INR | -7046.289% |
| Ajanta Pharma Limited | -954.9 Million INR | 71.966% |
| Alkem Laboratories Limited | -1.6 Billion INR | 83.366% |
| Alpa Laboratories Limited | 35.36 Million INR | 857.006% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 106.925% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 94.659% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 107.248% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 108.115% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 76.878% |
| Brooks Laboratories Limited | 49.48 Million INR | 640.972% |
| Divi's Laboratories Limited | -39.77 Billion INR | 99.327% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 102.073% |
| Eris Lifesciences Limited | 13.8 Billion INR | 101.939% |
| FDC Limited | -57.75 Million INR | -363.534% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 93.753% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 90.583% |
| Granules India Limited | 9.28 Billion INR | 102.883% |
| Gufic Biosciences Limited | 3.19 Billion INR | 108.381% |
| Hester Biosciences Limited | 2.29 Billion INR | 111.686% |
| Indoco Remedies Limited | 6.47 Billion INR | 104.134% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 93.554% |
| Ipca Laboratories Limited | 11.41 Billion INR | 102.345% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 80.74% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 113.85% |
| Lasa Supergenerics Limited | 205.79 Million INR | 230.078% |
| Laurus Labs Limited | 24.38 Billion INR | 101.098% |
| Lupin Limited | 17.19 Billion INR | 101.557% |
| Mankind Pharma Limited | -9.9 Billion INR | 97.298% |
| Medicamen Biotech Limited | 160.31 Million INR | 266.983% |
| Medico Remedies Limited | 78.67 Million INR | 440.252% |
| Megasoft Limited | 1.28 Billion INR | 120.824% |
| Piramal Pharma Limited | 42.27 Billion INR | 100.633% |
| RPG Life Sciences Limited | -364.7 Million INR | 26.597% |
| Sigachi Industries Limited | 859.94 Million INR | 131.13% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 71.576% |
| Unichem Laboratories Limited | 931.91 Million INR | 128.726% |
| Wanbury Limited | 1.1 Billion INR | 124.207% |
| Windlas Biotech Limited | -273.04 Million INR | 1.956% |
| ZIM Laboratories Limited | 983.6 Million INR | 127.216% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 106.843% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 88.599% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -7.6% |
| Bal Pharma Limited | 1.26 Billion INR | 121.186% |
| Strides Pharma Science Limited | 23.25 Billion INR | 101.151% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 110.249% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 104.348% |
| Shilpa Medicare Limited | 9.06 Billion INR | 102.952% |
| Aarti Drugs Limited | 5.54 Billion INR | 104.825% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 75.692% |
| Suven Life Sciences Limited | -1.63 Billion INR | 83.604% |
| Ind-Swift Limited | 9.5 Billion INR | 102.815% |
| Valiant Laboratories Limited | -295.03 Million INR | 9.264% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 109.489% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 102.669% |
| Themis Medicare Limited | 764.96 Million INR | 134.995% |
| Hikal Limited | 7.96 Billion INR | 103.36% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 100.841% |
| Sequent Scientific Limited | 4.17 Billion INR | 106.406% |
| Novartis India Limited | -5.89 Billion INR | 95.456% |
| Wockhardt Limited | 18.27 Billion INR | 101.465% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 100.989% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -1351.263% |
| Neuland Laboratories Limited | -214.05 Million INR | -25.06% |
| Morepen Laboratories Limited | -231.17 Million INR | -15.8% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 323.011% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 127.434% |